R&D News | pharmaphorum

News

MSD steps out with Protillion in $510m+ AI shindig

MSD has teamed up with Protillion Bio in a deal worth more than $510m, focusing on using the AI start-up's lab-in-the-loop platform for drug discovery

News

Jeremy Skillington, Poolbeg's chief executive

Poolbeg expects first data for CRS drug in the summer

A trial to see if Poolbeg's POLB-001 can prevent cytokine release syndrome in multiple myeloma treated with immunotherapy Tecvayli will start soon.

News

Lilly trumpets strong result for Jaypirca in CLL at EHA

New data with Eli Lilly's Jaypirca at EHA 2026 has cemented its place as a second-line therapy for chronic lymphocytic leukaemia.

News

Key pipeline drug for Lundbeck delivers in Cushing syndrome

Lundbeck has reported positive trial results with Cushing's therapy asedebart, a key R&D prospect as it faces a patent cliff in the next few years.

News

Two boxes and vials of Talvey, different doses

Data could move J&J's Talvey earlier in myeloma therapy

Johnson & Johnson's Talvey looks set to move second-line in multiple myeloma treatment, based on the results of the MonumenTAL-3 trial at EHA 2026.

News

NHS study launched to tackle antimicrobial resistance threat

A new study will attempt to improve screening for CPE, one of the fastest-growing drug-resistant bacterial threats facing hospitals in England.

MSD steps out with Protillion in $510m+ AI shindig

Poolbeg expects first data for CRS drug in the summer

Lilly trumpets strong result for Jaypirca in CLL at EHA

Key pipeline drug for Lundbeck delivers in Cushing syndrome

Data could move J&J's Talvey earlier in myeloma therapy

NHS study launched to tackle antimicrobial resistance threat

ESMO26: Neoadjuvant Enhertu fails in early breast cancer

Discover a new era of healthcare panel engagement: Grounded ...

News

Editor's Picks